(0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I

Sunday, October 26, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
Abstract Poster Presenter: Zhenping Zhu, n/a – Helixon Therapeutics
10:30 AM - 12:30 PM Central Time

Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Abstract Poster Presenter: Minyun Zhou, PhD – Simcere Pharmaceutical Group
10:30 AM - 12:30 PM Central Time

Pharmacology Analyses of Sail’s In Vivo hCD19 CAR-T Product Reveal Mechanistic Insights Underlying its Optimal Dose Efficiency Profile in Both Healthy Donors and SLE Patient Samples
Abstract Poster Presenter: Siobhan Rice, PhD – Sail Biomedicines
10:30 AM - 12:30 PM Central Time

CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Abstract Poster Presenter: Philipp Richle, -None- – CDR-Life
10:30 AM - 12:30 PM Central Time

XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Abstract Poster Presenter: Matthew Bernett, PhD – Xencor, Inc.
10:30 AM - 12:30 PM Central Time

NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Abstract Poster Presenter: Mira Tohmé, PhD – nkarta therapeutics
10:30 AM - 12:30 PM Central Time

QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Abstract Poster Presenter: Jenny McGovern, PhD – Quell Therapeutics
10:30 AM - 12:30 PM Central Time

MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Fas^lpr Mouse Model
Abstract Poster Presenter: Marisa Peluso, MS – Monte Rosa Therapeutics
10:30 AM - 12:30 PM Central Time

KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Abstract Poster Presenter: Brian Kim, MS – Kite, a Gilead Company
10:30 AM - 12:30 PM Central Time

In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Abstract Poster Presenter: Edo Kon, PhD, MBA (he/him/his) – RiboX Therapeutics
10:30 AM - 12:30 PM Central Time

KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
Abstract Poster Presenter: Min Bao, MD – Kali Therapeutics
10:30 AM - 12:30 PM Central Time

LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Abstract Poster Presenter: Hong Ling, n/a – Nanjing Leads Biolabs Co., Ltd.
10:30 AM - 12:30 PM Central Time

KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
Abstract Poster Presenter: Min Bao, MD – Kali Therapeutics
10:30 AM - 12:30 PM Central Time

ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Abstract Poster Presenter: Bing Hou, PhD – Antengene. Corp.
10:30 AM - 12:30 PM Central Time

Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Abstract Poster Presenter: Julia Manasson, MD, MS – Seismic Therapeutic